Infinity Pharmaceuticals Inc. (INFI) Receives $1.55 Average Price Target from Analysts

Analysts rating the company a 3 indicate a Hold recommendation. The average 12-month price target among analysts that have issued a report on the stock in the previous year is $1.55.

Many research firms have provided their ratings on Merrimack Pharmaceuticals, Inc. Wedbush reaffirmed a "neutral" rating and set a $1.00 target price (down from $1.25) on shares of Infinity Pharmaceuticals in a report on Tuesday, August 9th. HC Wainwright reaffirmed a "buy" rating and set a $10.00 price target on shares of Aurinia Pharmaceuticals in a research report on Wednesday, October 5th. Finally, Needham & Company LLC restated a "buy" rating and issued a $38.00 target price on shares of Adamas Pharmaceuticals in a research note on Wednesday, July 20th.

Recently stock market analysts updated their outstanding price targets on shares of AcelRx Pharmaceuticals, Inc. (:PTN) moved -1.99% from the open. Drilling down, the stock is 4.07% for the past month and -1.92% for the week. (ACRX) was down -0.88% during the last trading session, with a day high of 3.47.

Titan Pharmaceuticals, Inc. (Titan) is a specialty pharmaceutical company.

Infinity Pharmaceuticals (NASDAQ:INFI) last announced its quarterly earnings data on Tuesday, August 9th. 0 analysts have suggested "Sell" for the company. The firm had revenue of $9.47 million for the quarter, compared to analysts' expectations of $13.91 million. This showed the surprise of -21.2% in the last quarter earnings. They now have a Dollars 8 price target on the stock. Bank of New York Mellon Corp owned about 0.47% of Rigel Pharmaceuticals worth $974,000 at the end of the most recent quarter. Finally, Abingworth LLP raised its stake in Aurinia Pharmaceuticals by 479.8% in the second quarter.

The share price of the company (TTNP) was down -8.33% during the last trading session, with a high of 5.98 and the volume of Titan Pharmaceuticals, Inc. shares traded was 371579. ClariVest Asset Management LLC increased its stake in Rigel Pharmaceuticals by 5.5% in the second quarter. Strs Ohio now owns 211,300 shares of the company's stock worth $471,000 after buying an additional 16,300 shares during the last quarter. Geode Capital Management LLC now owns 731,016 shares of the company's stock worth $1,520,000 after buying an additional 75,321 shares during the last quarter. ProShare Advisors LLC boosted its position in Adamas Pharmaceuticals by 4.6% in the second quarter. Also, Director William W. Ericson acquired 43,719 shares of the business's stock in a transaction that occurred on Friday, September 2nd. Creative Planning bought a new stake in Aurinia Pharmaceuticals during the third quarter worth about $181,000. The Company operates through the segment, which includes development and commercialization of product candidates for the treatment of pain.

AcelRx Pharmaceuticals, a pharmaceutical company focused on the development and commercialization of therapies for the treatment of moderate-to-severe acute pain. The Company develops small molecule drugs that target disease pathways for potential applications in oncology.

Vanessa Coleman